Michal Bista

Michal Bista

Auto-generated profile, based on publicly available information

Michal Bista

Medical Research Council Laboratory of Molecular Biology, Cambridge, England

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2008 in Nature Methods
Verified
Journal Article
Closed access
PDF file
JRJulia Riedl
Julia Riedl
ACAlvaro Hernan Crevenna
Alvaro Hernan Crevenna
KKKai Kessenbrock
Kai Kessenbrock
JYJerry Haochen Yu
Jerry Haochen Yu
DNDorothee Neukirchen
Dorothee Neukirchen
RWRoland Wedlich-Söldner
Roland Wedlich-Söldner

16 July 2010 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
ACAnna Czarna
Anna Czarna
BBBarbara Beck
Barbara Beck
SSStuti Srivastava
Stuti Srivastava
GPGrzegorz M. Popowicz
Grzegorz M. Popowicz
SWSiglinde Wolf
Siglinde Wolf
ADAlexander Dömling
Alexander Dömling

12 March 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DKDavid Koes
David Koes
KKKareem Khoury
Kareem Khoury
YHYijun Huang
Yijun Huang
WWwei wang
wei wang
MBMichal Bista
Michal Bista
CCCarlos Camacho
Carlos Camacho
Although there is no shortage of potential drug targets, there are only a handful known low-molecular-weight inhibitors of protein-protein interactions (PPIs). One problem is that current efforts are dominated by low-yield high-throughput screening, whose rigid framework is not suitable for the diverse chemotypes present in PPIs. Here, we developed a novel pharmacophore-based interactive screening technology that builds on the role anchor residues, or deeply buried hot spots, have in PPIs, and redesigns these entry points with anchor-biased virtual multicomponent reactions, delivering tens of millions of readily synthesizable novel compounds. Application of this approach to the MDM2/p53 cancer target led to high hit rates, resulting in a large and diverse set of confirmed inhibitors, and co-crystal structures validate the designed compounds. Our unique open-access technology promises to expand chemical space and the exploration of the human interactome by leveraging in-house small-scale assays and user-friendly chemistry to rationally design ligands for PPIs with known structure.

9 July 2010 in Chemical Biology & Drug Design
Verified
Journal Article
Open access
PDF file
YHYijun Huang
Yijun Huang
SWSiglinde Wolf
Siglinde Wolf
MBMichal Bista
Michal Bista
LMLidio Meireles
Lidio Meireles
CCCarlos Camacho
Carlos Camacho
ADAlexander Dömling
Alexander Dömling
1,4‐Thienodiazepine‐2,5‐diones have been synthesized via the Ugi‐Deprotection‐Cyclization (UDC) approach starting from Gewald 2‐aminothiophenes in a convergent and versatile manner. The resulting scaffold is unprecedented, cyclic, and peptidomimetic with four points of diversity introduced from readily available starting materials. In addition to eighteen synthesized and characterized compounds, a virtual compound library was generated and evaluated for chemical space distribution and drug‐like properties. A small focused compound library of 1,4‐thienodiazepine‐2,5‐diones has been screened for the activity against p53‐Mdm2 interaction. Biological evaluations demonstrated that some compounds exhibited promising antagonistic activity.

14 April 2009 in Biochemical Journal
Verified
Journal Article
Closed access
JSJustyna Stec-Niemczyk
Justyna Stec-Niemczyk
KPKatarzyna Pustelny
Katarzyna Pustelny
MKMagdalena Kisielewska
Magdalena Kisielewska
MBMichal Bista
Michal Bista
KBKevin T. Boulware
Kevin T. Boulware
GDGrzegorz Dubin
Grzegorz Dubin
Staphylococcus aureus is a dangerous human pathogen whose antibiotic resistance is steadily increasing and no efficient vaccine is as yet available. This serious threat drives extensive studies on staphylococcal physiology and pathogenicity pathways, especially virulence factors. Spl (serine protease-like) proteins encoded by an operon containing up to six genes are a good example of poorly characterized secreted proteins probably involved in virulence. In the present study, we describe an efficient heterologous expression system for SplA and detailed biochemical and structural characterization of the recombinant SplA protease. The enzyme shares a significant sequence homology to V8 protease and epidermolytic toxins which are well documented staphylococcal virulence factors. SplA has a very narrow substrate specificity apparently imposed by the precise recognition of three amino acid residues positioned N-terminal to the hydrolysed peptide bond. To explain determinants of this extended specificity we resolve the crystal structure of SplA and define the consensus model of substrate binding. Furthermore we demonstrate that artificial N-terminal elongation of mature SplA mimicking a naturally present signal peptide abolishes enzymatic activity. The probable physiological role of the process is discussed. Of interest, even though precise N-terminal trimming is a common regulatory mechanism among S1 family enzymes, the crystal structure of SplA reveals novel significantly different mechanistic details.

1 May 2008 in Journal of Molecular Biology
Verified
Journal Article
Closed access
GDGrzegorz Dubin
Grzegorz Dubin
JSJustyna Stec-Niemczyk
Justyna Stec-Niemczyk
MKMagdalena Kisielewska
Magdalena Kisielewska
KPKatarzyna Pustelny
Katarzyna Pustelny
GPGrzegorz M. Popowicz
Grzegorz M. Popowicz
JPJan Potempa
Jan Potempa